Bivalent Hapten Display Strategies for Conjugate Vaccines Targeting Opioid Mixtures Containing Fentanyl

Area of Science:

• Pharmacology
• Immunology
• Medicinal Chemistry

Background:

• Street opioids increasingly involve mixtures of synthetic opioids like fentanyl and its analogues.
• Current anti-opioid immunotherapeutics target specific opioids, limiting broad efficacy.
• There's a need for conjugate vaccines that can simultaneously target multiple opioid substances.

Purpose of the Study:

• To synthesize novel haptens for developing anti-opioid conjugate vaccines.
• To evaluate the efficacy of bivalent vaccines against fentanyl, carfentanil, alfentanil, and oxycodone.
• To compare bivalent vaccines with admixed monovalent vaccines for broader opioid blockade.

Main Methods:

• Synthesis of four novel haptens designed for broad opioid binding.
• Conjugation of haptens to CRM carrier protein and formulation with adjuvant.
• Immunization of rats with monovalent, admixed, or bivalent vaccines.
• Assessment of opioid blockade, antibody titers, and in vivo effects (antinociception, respiratory depression, brain distribution).

Main Results:

• Bivalent vaccines showed reduced effects of some target opioids.
• Admixed vaccine formulations were more effective against fentanyl/carfentanil and fentanyl/alfentanil mixtures.
• A bivalent fentanyl/oxycodone vaccine performed comparably to monovalent vaccines against single drug challenges.

Conclusions:

• Admixed vaccine formulations demonstrated superior efficacy against certain opioid mixtures compared to bivalent designs.
• Results provide insights for designing future opioid vaccines, especially for polysubstance use.
• Optimization of immune response against multiple drugs is key for effective vaccine development.